RxDoctor Payments DataLook up a doctor →

Vasvi Singh, MD

Cardiovascular Disease · Overland Park, KSNPI 1659652816

Payments from drug & device makers

$435,643in general payments, 2019–2025

Across 440 payments — averaging $990.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$163K
  • Pfizer$139K
  • Bridgebio Pharma, Inc.$73K
  • Novartis$30K
  • Alnylam Pharmaceuticals Inc.$22K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$7K
  • plus $2K from 20 others

What the payments were for

  • Consulting fees$36,6789%
  • Speaking & faculty fees$287,66871%
  • Grants$18,4365%
  • Travel & lodging$53,17613%
  • Food & beverage$9,2292%
  • Education$890%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$435,643 in reported general payments places this provider in the 95th percentile of 175 cardiovascular disease providers in Kansas.

See all cardiovascular disease providers in Kansas

Medicare billing

Part B allowed, 2024
$109,513
Medicare patients
716
Services billed
1,630

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis70$1,726,898
EliquisApixaban12$16,724
JardianceEmpagliflozin11$6,393
Metoprolol Succinate52$671
Atorvastatin Calcium55$481
Losartan Potassium36$410
Amlodipine Besylate43$202
Ezetimibe18$195
Spironolactone28$164
Carvedilol17$158
Furosemide25$109
Rosuvastatin Calcium11$93
Hydrochlorothiazide13$7

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$139,125$1,743,62282 claims
Boehringer IngelheimJardiance$133$6,39311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 175 cardiovascular disease providers in Kansas.

Other cardiovascular disease in Overland Park

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →